Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Benefit-Cost Analysis | Health Outcomes | Policy/Regulation | Mental Health | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
Online LearningVideo, Teaching Resource 2017Forum. The Opioid Crisis: A Governors Roundtable
Opioid overdoses claim the lives of 91 Americans every day, according to the Centers for …
Opioid overdoses claim the lives of 91 Americans every day, according to the Centers for Disease Control and Prevention. This Forum - The Opioid Crisis: A Governors Roundtable, is part of the series, Policy Controversies, and was presented jointly with PRI’s The World & WGBH News. In this multimedia forum, four former governors offered candid insights into how government policy can help, exploring what works and what doesn’t. They spoke about experiences within their own…
Priority Setting/Ethics | Health Outcomes | Policy/Regulation | Mental Health | Chronic Disease/Risk | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | North America | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
Working PaperPublication 2024Economic Evaluation Primer
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence …
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence needed to support sound policy decisions. In low- and middle-income countries, where resources are especially scarce and needs are very great, such decisions are exceptionally difficult. In these settings, economic evaluation can be particularly useful in determining how to best improve health and welfare. Typically, cost-effectiveness analysis (CEA) is used to prioritize interventions within the health care sector. This approach…
Priority Setting/Ethics | Benefit-Cost Analysis | Health Outcomes | Policy/Regulation | Costing Methods | Cost-Effectiveness Analysis | Global -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Decision Theory | State-Transition | Health Outcomes | Policy/Regulation | Costing Methods | Decision Analysis | Infectious Diseases | Economics/Finance | Government/Law | Health/Medicine | Middle East & North Africa -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | State-Transition | Value of Information | Policy/Regulation | Infectious Diseases | Economics/Finance | North America | Europe -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Priority Setting/Ethics | Benefit-Cost Analysis | Health Outcomes | Policy/Regulation | Preferences/Values | Decision Analysis | Social Determinants | Economics/Finance | Health/Medicine | Global | Critical Thinking/Analysis -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Priority Setting/Ethics | Health Outcomes | Value of Information | Policy/Regulation | Preferences/Values | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Global -
BookPublication 2012Elgar Companion to Health Economics, 2nd Edition
This collection brings together more than 50 contributions from some of the most influential researchers in …
This collection brings together more than 50 contributions from some of the most influential researchers in health economics. It covers theoretical and empirical issues in health economics, with a range of material on equity and efficiency in health care systems, health technology assessment and issues of concern for developing countries. This revised second edition is expanded to include four new chapters, while all existing chapters have been extensively updated. The Elgar Companion to Health Economics, Second Edition…
Priority Setting/Ethics | Decision Theory | Value of Information | Policy/Regulation | Probability/Bayes | Preferences/Values | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Priority Setting/Ethics | Health Outcomes | Value of Information | Policy/Regulation | Preferences/Values | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | North America